Shashi Singh
The distribution of anti-osteoporotic medications at the right dose has proven difficult due to the lack of safety, efficacy, and specificity. In our research, bone-specific polyaspartic acid Asp) 8-DNPs were added to cathepsin K inhibitor loaded poly derived lipid hybrid nanoparticles to cure osteoporosis. DNPs shown their affinity for binding to hydroxyapatite and were successful in releasing cathepsin K inhibitors over the course of up to 5 days. The tartrate-resistant acid phosphatase activity and resorption-related genes in osteoclasts were drastically reduced by cathepsin K inhibitor loaded Asp 8-DNPs. The tibia and femur of animals showed high levels of Asp 8-DNP accumulation, as well as increased trabecular bone mass and more organised three-dimensional architecture in osteoporotic rat models. Herein, the bone targeted drug delivery system show its potential in treatment of osteoporosis
KeywordsBone-targeting; Polyaspartic acid peptides; Drug delivery system; Osteoporosis; Anti-osteoporosis drug